XOMA Royalty Corporation (NASDAQ:XOMA – Get Free Report)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $31.74 and traded as high as $41.92. XOMA Royalty shares last traded at $41.80, with a volume of 142,874 shares traded.
Analyst Ratings Changes
Several equities research analysts have issued reports on XOMA shares. HC Wainwright downgraded XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price target for the company. in a report on Thursday, April 30th. Zacks Research upgraded XOMA Royalty from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. Benchmark downgraded XOMA Royalty from a “buy” rating to a “hold” rating in a report on Friday, May 22nd. Weiss Ratings upgraded XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 29th. Finally, Lucid Cap Mkts downgraded XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, XOMA Royalty has an average rating of “Hold” and a consensus price target of $53.75.
XOMA Royalty Stock Down 0.0%
XOMA Royalty (NASDAQ:XOMA – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.02). The firm had revenue of $12.32 million for the quarter, compared to analyst estimates of $13.91 million. XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%. As a group, sell-side analysts anticipate that XOMA Royalty Corporation will post 0.9 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Nano Cap New Millennium Growth Fund L P acquired a new position in XOMA Royalty during the fourth quarter valued at approximately $399,000. State of Alaska Department of Revenue acquired a new position in XOMA Royalty during the fourth quarter valued at approximately $27,000. Diversified Management Inc. acquired a new position in XOMA Royalty during the fourth quarter valued at approximately $266,000. SG Americas Securities LLC acquired a new position in XOMA Royalty during the fourth quarter valued at approximately $169,000. Finally, Man Group plc acquired a new position in XOMA Royalty during the third quarter valued at approximately $247,000. 95.92% of the stock is owned by institutional investors and hedge funds.
About XOMA Royalty
XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.
The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.
Featured Articles
- Five stocks we like better than XOMA Royalty
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for XOMA Royalty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Royalty and related companies with MarketBeat.com's FREE daily email newsletter.
